ATE408601T1 - Fredericamycin-derivate - Google Patents

Fredericamycin-derivate

Info

Publication number
ATE408601T1
ATE408601T1 AT03718715T AT03718715T ATE408601T1 AT E408601 T1 ATE408601 T1 AT E408601T1 AT 03718715 T AT03718715 T AT 03718715T AT 03718715 T AT03718715 T AT 03718715T AT E408601 T1 ATE408601 T1 AT E408601T1
Authority
AT
Austria
Prior art keywords
derivatives
fredericamycin derivatives
fredericamycin
salts
diseases
Prior art date
Application number
AT03718715T
Other languages
English (en)
Inventor
Simon Werner
Ulrich Abel
Original Assignee
Biofrontera Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofrontera Discovery Gmbh filed Critical Biofrontera Discovery Gmbh
Application granted granted Critical
Publication of ATE408601T1 publication Critical patent/ATE408601T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Saccharide Compounds (AREA)
AT03718715T 2002-04-17 2003-03-28 Fredericamycin-derivate ATE408601T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10217046A DE10217046A1 (de) 2002-04-17 2002-04-17 Fredericamycin-Derivate

Publications (1)

Publication Number Publication Date
ATE408601T1 true ATE408601T1 (de) 2008-10-15

Family

ID=28798497

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03718715T ATE408601T1 (de) 2002-04-17 2003-03-28 Fredericamycin-derivate

Country Status (8)

Country Link
US (1) US7459462B2 (de)
EP (1) EP1495003B1 (de)
JP (1) JP4624685B2 (de)
AT (1) ATE408601T1 (de)
AU (1) AU2003222785B2 (de)
CA (1) CA2482775A1 (de)
DE (2) DE10217046A1 (de)
WO (1) WO2003087060A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080582A2 (de) * 2002-03-26 2003-10-02 Biofrontera Discovery Gmbh Fredericamycin-derivate
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
EP1919873A1 (de) * 2005-09-01 2008-05-14 BioAgency AG Fredericamycin-derivate
CA2909277A1 (en) 2006-04-04 2007-10-11 Kevan M. Shokat Kinase antagonists
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (de) 2008-03-14 2018-06-27 Intellikine, LLC Kinasehemmer und verwendungsverfahren
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2427195B1 (de) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclische verbindungen und ihre verwendung
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
EP2571357B1 (de) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemische verbindungen, zusammensetzungen und verfahren zur kinasemodulation
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
DK2663309T3 (en) 2011-01-10 2017-06-19 Infinity Pharmaceuticals Inc METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
EP2678018A4 (de) 2011-02-23 2015-09-30 Intellikine Llc Kombination von kinasehemmern und verwendungen dafür
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013323426A1 (en) 2012-09-26 2015-04-23 The Regents Of The University Of California Modulation of ire1
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
PL3052485T3 (pl) 2013-10-04 2022-02-28 Infinity Pharmaceuticals, Inc. Związki heterocykliczne i ich zastosowania
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
IL263680B2 (en) 2016-06-24 2025-10-01 Infinity Pharmaceuticals Inc PI3K inhibitors for use in combination with a second therapeutic agent for the treatment, management or prevention of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584377A (en) 1983-08-18 1986-04-22 Ss Pharmaceutical Co., Ltd. Novel Fredericamycin A derivatives
JPS6144868A (ja) * 1984-08-09 1986-03-04 Ss Pharmaceut Co Ltd 新規なフレデリカマイシンa誘導体
US4673678A (en) 1986-07-25 1987-06-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble derivatives of fredericamycin A
US5166208A (en) * 1991-10-09 1992-11-24 Boston College Fredericamycin A derivatives
JP4351310B2 (ja) * 1998-08-31 2009-10-28 泰行 北 新規スピロ系多環式化合物及びその製造方法

Also Published As

Publication number Publication date
DE10217046A1 (de) 2003-11-06
AU2003222785A1 (en) 2003-10-27
WO2003087060A1 (de) 2003-10-23
CA2482775A1 (en) 2003-10-23
DE50310516D1 (de) 2008-10-30
JP4624685B2 (ja) 2011-02-02
US7459462B2 (en) 2008-12-02
JP2005528396A (ja) 2005-09-22
EP1495003A1 (de) 2005-01-12
US20050153997A1 (en) 2005-07-14
AU2003222785B2 (en) 2009-04-23
EP1495003B1 (de) 2008-09-17

Similar Documents

Publication Publication Date Title
ATE408601T1 (de) Fredericamycin-derivate
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2003080582A3 (de) Fredericamycin-derivate
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
BR0312729A (pt) Novos derivados de indol-3-enxofre
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
SE0301700D0 (sv) Novel compounds
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
ATE448232T1 (de) Substituierte heterozyklen
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
MXPA04005809A (es) Inhibidores de proteinas quinasas.
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
SE0200198D0 (sv) New use